All Updates

All Updates

icon
Filter
Partnerships
AbCellera and RQ Bio partner to identify antibodies for infectious diseases
AI Drug Discovery
Mar 22, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Mar 22, 2023

AbCellera and RQ Bio partner to identify antibodies for infectious diseases

Partnerships

  • Vancouver-based AI drug discovery company AbCellera Biologics entered a strategic collaboration with British biotechnology company RQ Bio to identify clinical candidates for three infectious disease targets chosen by RQ Bio, including influenza and cytomegalovirus (CMV). 

  • The partnership combines RQ Bio’s experience in viral and infectious diseases with AbCellera’s discovery engine, enabling faster development of new medicines for high-risk patients.

  • Under the terms of the agreement, AbCellera will receive payments for research and could receive additional payments upon completion of clinical and regulatory milestones, as well as a percentage of product sales revenue. RQ Bio is authorized to advance and market therapeutic antibodies generated from the partnership.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.